{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:24:25Z","timestamp":1794079465456,"version":"4.8.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDR"],"published-print":{"date-parts":[[2017,7,25]]},"DOI":"10.2174\/1573399812666160613113556","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T23:49:16Z","timestamp":1466812156000},"source":"Crossref","is-referenced-by-count":219,"title":["Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials"],"prefix":"10.2174","volume":"13","author":[{"given":"Matthew J.","family":"Levine","sequence":"first","affiliation":[{"name":"10666 North Torrey Pines Road, La Jolla, CA 92037, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/143241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T08:55:49Z","timestamp":1500972949000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/143241\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399812666160613113556","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}